All In Biotech

Drug Trial Radar · NCT07364877

A Phase 1 Clinical Trial to Evaluate the Safety and Pharmacokinetics of DW4421 and DW4421S in Healthy Adult Volunteers

A Randomized, Open-label, Single-dose, 2-sequence, Two-period, Crossover Phase 1 Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics After Administration of DW4421 and DW4421S in Healthy Adult Volunteers

Last checked: Nov 20, 2026Latest source record: Jan 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Enrolling by invitation

Status

Enrolling by invitation

Enrollment

38

Planned (sponsor's estimate)

Start

Dec 28, 2025

Primary completion

Mar 19, 2026

Study completion May 18, 2026

Sponsor

Sponsor type
Industry
First posted
Jan 23, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Basic science
FDA-regulated drug
No
Who can join
All sexes, from 19 years, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Safety and pharmacokinetic characteristics evaluation of DW4421 and DW4421S

Conditions

  • Healthy Adult Volunteer

Interventions

  • DW4421Drug

    DW4421 or DW4421S

  • DW4421SDrug

    DW4421 or DW4421S

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. CmaxTime frame: up to 48 hour
  2. AUC0-tTime frame: up to 48 hour

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Chungbuk National University Hospital

    Cheongju-si, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.